Familial Amyloid Polyneuropathy Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The Global Familial Amyloid Polyneuropathy Market is anticipated to register a CAGR of 5% during forecast period 2022-2028.

Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy is a genetic disorder caused by the deposition of insoluble amyloid fibrils in various tissues, including around peripheral nerves and in heart muscle. Transthyretin is a carrier of retinol and thyroid hormone. Most of it is made in the liver, and small amounts of protein are made in the brain and eyes. The prevalence of familial amyloid polyneuropathy is very low worldwide. According to a review article published in Lancet Neurology, cases of FAP have been reported worldwide, but strong genotypic heterogeneity exists in Europe. The article also notes that 30 different TTR gene mutations have been reported in Japan and France.

Market Segments

By Type:

• FAP-I
• FAP-II
• FAP-III
• FAP-IV

By Application:

• Hospitals and Clinics
• Others

Key Players

• Pfizer
• GSK
• Ionis
• Alnylam
• Corino Therapeutics
• Proclara Bioscience
• Arcturus Therapeutics

Scope of the Report

The research study analyzes the global Familial Amyloid Polyneuropathy industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by Familial Amyloid Polyneuropathy Market Report

1. What was the Familial Amyloid Polyneuropathy Market size in 2019 and 2020; what are the estimated growth trends and market forecast (2022-2028).

2. What will be the CAGR of Familial Amyloid Polyneuropathy Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Familial Amyloid Polyneuropathy Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.